Abstract
Radiolabeled liposomes have been employed as diagnostic tools to monitor in vivo distribution of liposomes in real-time, which helps in optimizing the therapeutic efficacy of the liposomal drug delivery. This work utilizes the platform of [111In]-Liposome as a drug delivery vehicle, encapsulating a novel 18F-labeled carboplatin drug derivative ([18F]-FCP) as a dual-molecular imaging tool as both a radiolabeled drug and radiolabeled carrier. The approach has the potential for clinical translation in individual patients using a dual modal approach of clinically-relevant radionuclides of 18F positron emission tomography (PET) and 111In single photon emission computed tomography (SPECT). [111In]-Liposome was synthesized and evaluated in vivo by biodistribution and SPECT imaging. The [18F]-FCP encapsulated [111In]-Liposome nano-construct was investigated, in vivo, using an optimized dual-tracer PET and SPECT imaging in a nude mouse. The biodistribution data and SPECT imaging showed spleen and liver uptake of [111In]-Liposome and the subsequent clearance of activity with time. Dual-modality imaging of [18F]-FCP encapsulated [111In]-Liposome showed significant uptake in liver and spleen in both PET and SPECT images. Qualitative analysis of SPECT images and quantitative analysis of PET images showed the same pattern of activity during the imaging period and demonstrated the feasibility of dual-tracer imaging of a single dual-labeled nano-construct.
Highlights
The unique in vivo information provided by molecular imaging has the capacity to improve the overall efficacy of cancer treatment
Already 18F-Fluorodeoxyglucose positron emission tomography ([18F]-FDG-PET) is integrated with cross-sectional imaging, in the form of positron emission tomography/computed tomography (PET/CT), which is commonly used in the management of cancer patients
It is inevitable that other molecular imaging technologies, such as molecular resonance imaging/molecular resonance spectroscopy (MRI/MRS), PET, single photon emission computed tomography (SPECT), and photoacoustic imaging, will be combined to better assess multiple biological factors contributing to disease progression and the working of therapies
Summary
The unique in vivo information provided by molecular imaging has the capacity to improve the overall efficacy of cancer treatment. There is growing demand by physicians, patients, and the community as a whole for personalized healthcare, and molecular imaging is well-positioned to play a major role in the era of precision medicine. Molecular imaging will become more and more multi-modal in nature, as different anatomical and molecular imaging techniques merge to complement each other. With the advancement of targeted multi-modality molecular imaging, it is likely that molecular imaging will provide a personalized molecular fingerprint of individual tumors, as the basis for “tailor made”. Molecular imaging will provide a personalized molecular fingerprint of individual tumors, as the basis Int. J. Secmhaetmicastischsoswhoinwgin[g11[111I1nI]n-]L-Lipipoososommeeaanndd iittss ccoommppoonneenntstsalaolnogngwiwthitehnceanpcsauplsauteladted [18F]-C[1a8Frb]-oCpalrabtoinp;latinD; SDPSEP-EP-EPGEG: : 11,,22--ddiisstteeaarrooyyll--ssnn--gglylycceerroo-3-3-p-phhoosspphhooeeththaannool-la-amminine-eN-N- -[methoxy (polye[tmhyeltehnoexgyl(ypcoolly)]etahmymlenoengiulymcosla)]lta. mmonium salt
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
